BridgeBio Pharma, Inc. (BBIO)

As of 14 August 2026, short interest in BBIO is 23,324,059 shares, down 2,426,590 shares over the last month. Over the last 48 readings it ranged from 16,998,642 shares (29 November 2024) to 25,750,649 shares (15 July 2026). At the reported average volume of 2.2M shares a day that is 10.8 days to cover, a crowded short.

<iframe src="https://xoomar.com/embed/stocks/bbio" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

As of 11 September 2026, the short share of BBIO volume is 50.6%, down 8.6 points over the last five sessions. Over the last 52 readings it ranged from 21.5% (8 September 2026) to 81.0% (16 July 2026). The latest reading is 2.3 points above the 30-session average of 48.3%, on 669K shares reported.

As of 5 August 2026, the fails-to-deliver balance in BBIO is 15,279 shares, up 15,269 shares over the last settlement date. Over the last 52 readings it ranged from 1 share (4 November 2025) to 1,697,839 shares (30 June 2026). The latest reading sits at the bottom of that range.

Insiders at BBIO reported 15 open-market sells worth $21.6M in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: Kumar Neil (Chief Executive Officer) on 2026-08-19.

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.

3 Form 144 notices on file for BBIO worth $7.0M at the prices reported; 3 in the last 90 days worth $7.0M. Latest: KUMAR HALDEA FAMILY IRREVOCABLE TRU/T/A DTD 05/18/2019 filed on 2026-08-19 to sell 30,000 shares ($2.5M) from 2026-08-19.

10 holders above 5% have filed on BBIO, 9 on Schedule 13D (active intent). The largest reported stake is BlackRock, Inc. at 5.0% of the class (9,733,762 shares), filed 2026-07-27 for an event on 2026-06-30.

10 of the 30 tracked managers held BBIO at their latest 13F, $1.99B in total at quarter-end prices. Viking Global Investors is the largest at $741.0M (2.1% of its portfolio) as of 2026-06-30. Over the prior quarter 8 added shares and 2 cut.

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

In Q2 2026 (quarter ended 2026-06-30) BridgeBio Pharma, Inc. reported revenue of $243.7M, up 120.4% from the same quarter a year earlier (-0.78 diluted EPS). In FY 2025 it generated -$445.9M of operating cash flow and spent $48.3M on buybacks. As of 2026-06-30, cash was $677.9M against $2.65B of debt.

Quarterly, last 8 quarters

Fiscal years, with buybacks and dividends

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-03 from the cover page.